Dutch vaccine developer Mucosis has announced that John Lambert has been elected as the new chairman of its supervisory board. Mucosis is developing vaccines based on particles created from inactivated Lactococcus lactis bacteria, including its lead candidate, an intranasal influenza vaccine called FluGEM. Read the company’s press release
Mucosis elects new chairman
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
